Search PubMed⌕ Search

Biomedical subjects

L Magyar

Publications and source records attributed to L Magyar.

8 recordsLinked to original sources
PubMed1998

Prevalence of impaired gastric emptying of solids in systemic sclerosis: diagnostic and therapeutic implications.

The aims of this study were to evaluate the gastric emptying of solids in patients with progressive systemic sclerosis, correlate the esophageal motility abnormalities with their gastric emptying status, delineate the symptoms suggestive of abnormal gastric emptying, and assess the effect of metoclopramide in patients with abnormally slow gastric emptying. Twenty patients underwent esophageal motility evaluation and gastric emptying studies with a radiolabeled solid meal. Gastric emptying was also measured in 13 healthy volunteers. Four patients in whom esophageal motility was normal also had an accompanying normal rate of gastric emptying. In 16 patients with abnormal esophageal motility, mean gastric emptying was significantly delayed as compared with that in normal subjects (67.4% vs 49.8% retention of isotope at 2 hours, P < .05). Ten patients had absolute criteria for slow gastric emptying (>+2 SD). However, only postprandial bloating and early satiety were symptoms that accurately predicted slow radionuclide emptying. In four of these patients in whom gastric emptying was slow, 10 mg intramuscular metoclopramide significantly (P < .05 vs baseline) accelerated the gastric emptying of the same test meal. We conclude that (1) gastric emptying of solids was delayed in approximately two thirds of patients with abnormal esophageal motility, whereas it was normal in patients with normal esophageal motor function; (2) metoclopramide significantly accelerated this slow gastric emptying; and (3) delayed gastric emptying contributes to the severity of the gastroesophageal reflux frequently present in patients with progressive systemic sclerosis, and promotility agents offer a valuable therapeutic approach.

Adult↗
PubMed1990

[Study of some official pharmaceutical preparations in the Sixth Edition of Formule Normales by thin-layer chromatography].

Pharmaceutical preparations--containing aminophenazonum, noraminophenazonum sodium mesylicum, acidum acetylsalicylicum and aethylmorphinium chloratum--official in the VI. Edition of Formulae Normales have been investigated. Simple method for studying decomposition products--which can be carried out in pharmacies and can be followed the quality of products with during their usability--has been developed. The method proving and precluding the presence of decomposition products, respectively by means of preparing dilution sets has been capable of semiquantitative determination of decomposition products. DC Alufolien Kieselgel 60 F254 (Merck) layer was used. Temperature of laboratory was 22-26 degrees C and its relative humidity was 30-40%. Developing solvents were: acetone-ether-water (90:15:12) for aminophenazum; benzene-acetone-90% alcohol-wated (35: 33: 26: 11) for noraminophenazonum sodium mesylicum; methenol-glacial acetic acid-ether-benzene (1: 18: 60: 120) for acidum acetylsalicylicum; dichloromethane-methanol-concentrated ammonia (85: 15: 2) for aethylmorphinium chloratum. Detections were carried out under UV light and by using colour reagents (alcoholic ninhydrine solution for aminophenazonum, dimethylamino-benzaldehyde solution for noraminophenazonum sodium mesylicum). Rf-values of intact and decomposed compounds have been given in figures. Interfering effects of other components of preparations were studied too. These components had different Rf-values or did not react with the colour producing reagents in the applied systems.

Chromatography, Thin Layer↗
PubMed1986

Self-curing animals.

Explore the source record for details and available documents.

Animal Population Groups↗
PubMed1985

[Not Available].

Explore the source record for details and available documents.

History, Early Modern 1451-1600↗
PubMed1984

Effects of nifedipine in achalasia and in patients with high-amplitude peristaltic esophageal contractions.

We studied the esophageal effects of nifedipine in 20 patients with achalasia (20 mg sublingually) and nine patients with high-amplitude peristaltic esophageal contractions (nutcracker esophagus) (20 mg orally). In patients with achalasia, nifedipine decreased lower esophageal sphincter (LES) pressure by approximately 30%. In ten patients with achalasia, plasma nifedipine concentrations were 45.3 +/- 17.7 and 57.4 +/- 12.8 ng/mL (means +/- SEM) at 30 and 60 minutes, respectively, after drug administration. In patients with nutcracker esophagus, nifedipine decreased LES pressure by approximately 50% and contraction amplitude in the body of the esophagus by approximately 25%. After comparison was made with our previous results in normal subjects, we concluded that (1) nifedipine decreased LES pressure in patients with achalasia to a similar extent to that noted in normal subjects; (2) plasma concentrations measured after 20 mg of nifedipine given sublingually to achalasic patients were similar to those found under similar circumstances in normal subjects; and (3) nifedipine decreased LES pressure and contraction amplitude in patients with nutcracker esophagus to a greater extent than was found in normal subjects. These results suggest that double-blind, placebo-controlled clinical trials of nifedipine in the treatment of achalasia or nutcracker esophagus are indicated.

Esophageal Achalasia↗